Phase 3 open-label trial of 13-valent pneumococcal conjugate vaccine in Alaskan Native children

Phase 3, open-label trial of pneumococcal 13-valent conjugate vaccine in pneumococcal disease, invasive pneumococcal disease (IPD), pneumonia and 1 more (5 arms), sponsored by Wyeth. Primary endpoints: Serotype-specific IgG response at threshold of 0.35 micrograms/mL after scheduled vaccination and Pre-vaccination serotype-specific IgG response in catch-up groups.